Ipamorelin dosage, as the studies administered it.

Read this first

This page describes what researchers gave to animals and to trial volunteers, and nothing more. It is not a how-to, and ipamorelin has no approved human dose — so you will not find a "take this much" number here, because none has been established in a controlled trial. The numbers worth knowing: in the one human study, the drug was given by IV (into a vein), and it cleared the body with a half-life of about 2 hours ^[2]. The community habit of self-injecting ipamorelin under the skin, often combined with CJC-1295, has no published human dosing basis at all. Where you see a dose below, it is always tied to a specific species and route from a specific study — that is the only honest way to talk about ipamorelin dosing.

Doses used in the studies

Every figure here is study-attributed, third person, and species-specific.

• Human PK/PD study: 4.21–140.45 nmol/kg by IV infusion over 15 minutes, as single doses ^[2].
• Human Phase 2 ileus RCT: 0.03 mg/kg IV twice daily for up to 7 days ^[3].
• Rat bone-growth study: 18, 90, and 450 microg/day subcutaneously, divided three times daily, over 15 days ^[4].
• Mouse adiposity study: twice-daily subcutaneous injection for 2 weeks ^[6].
• Ferret cachexia study (2024): 1–3 mg/kg intraperitoneal ^[5].

Notably, the rat bone-growth doses raised growth rate without moving systemic IGF-1 ^[4], and the mouse adiposity doses raised fat and leptin even in GH-deficient animals ^[6] — a reminder that dose-response for ipamorelin is not a simple "more equals more GH equals leaner."

Half-life and pharmacokinetics

In healthy human volunteers, ipamorelin showed a terminal half-life of approximately 2 hours after IV administration, with clearance 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg ^[2]. The growth-hormone response is a single discrete pulse peaking around 40 minutes (0.67 h) after dosing — not a sustained elevation ^[2]. Kinetics were dose-proportional across the tested range, meaning the body handled larger doses in a predictable, linear way ^[2]. These are the only published human pharmacokinetic figures for the compound.

Routes studied

Ipamorelin has been administered by several routes across the literature: intravenous (the human PK study and clinical trial, plus rodent efficacy work) ^[2][3]; subcutaneous (the dominant route in rodent bone and body-composition studies, and the route most used in community settings) ^[4][6]; and intraperitoneal (rodent and ferret efficacy studies) ^[5]. Ipamorelin itself is not orally bioavailable — only engineered analogs derived from its scaffold achieved meaningful oral absorption in animal work. The mismatch between the studied routes (mostly IV in humans) and the community route (subcutaneous self-injection) is one reason human safety data does not transfer cleanly to real-world use.

How much cjc-1295 ipamorelin should i take?

No evidence-based human dose exists for the CJC-1295 + ipamorelin combination, and none is provided here. There is no controlled human trial of the pairing for any outcome, so any specific microgram figure circulating online is a community convention, not a clinically validated dose ^[15]. What the literature does establish is single-agent pharmacology: ipamorelin's human data is confined to IV doses in a PK study and a failed Phase 2 trial ^[2][3], and CJC-1295's GH/IGF-1 kinetics were characterized separately ^[11]. Because ipamorelin has no approved indication and the combination is untested, this digest describes only what was studied — it does not recommend a dose.

How to reconstitute cjc-1295 ipamorelin 5mg?

Reconstitution is a research-handling step, not a clinical preparation instruction, and this digest does not provide a step-by-step human-use protocol. As background from the research-supply literature: ipamorelin is supplied as a lyophilized (freeze-dried) powder, as free base or acetate salt, and is reconstituted with bacteriostatic water for handling. Like any peptide, it degrades with heat and repeated freeze-thaw, so reconstituted solution is typically kept refrigerated. These are general stability observations, not directions for human dosing or self-administration, and the combination product has no approved preparation standard ^[3].